Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Y-Mabs Therapeutics Inc
(NQ:
YMAB
)
13.81
-0.25 (-1.78%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Y-Mabs Therapeutics Inc
< Previous
1
2
3
4
5
6
Next >
YMAB SHAREHOLDER ALERT: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - YMAB
February 19, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Y-mAbs, Bioventus, ESS, and IBM and Encourages Investors to Contact the Firm
February 13, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – YMAB
February 13, 2023
From
The Rosen Law Firm PA
Via
GlobeNewswire
The Latest Analyst Ratings for Y-mAbs Therapeutics
January 27, 2023
Via
Benzinga
YMAB SHAREHOLDER ALERT: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Y-mAbs Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - YMAB
February 12, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioLineRx, Enovix, Southwest Airlines, and Y-mAbs and Encourages Investors to Contact the Firm
February 08, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
YMAB LOSS ALERT: ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – YMAB
February 08, 2023
From
The Rosen Law Firm PA
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioLineRx, Enovix, Southwest Airlines, and Y-mAbs and Encourages Investors to Contact the Firm
February 03, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of Y-mAbs Therapeutics, Inc. (YMAB) Investors and Encourages Investors to Contact the Firm Before March 20, 2023
February 01, 2023
From
Kirby McInerney LLP
Via
Business Wire
Bronstein, Gewirtz & Grossman, LLC Notifies Y-mAbs Therapeutics, Inc. (YMAB) Investors of Class Action and to Actively Participate
January 30, 2023
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioLineRx, Enovix, Southwest Airlines, and Y-mAbs and Encourages Investors to Contact the Firm
January 29, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
TOP RANKED ROSEN LAW FIRM Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - YMAB
January 29, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
Y-mAbs Therapeutics, Inc. (YMAB) Investor Alert: Robbins LLP Reminds Shareholders of Class Action Against Y-mAbs Therapeutics, Inc.
January 27, 2023
From
Robbins LLP
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For January 27, 2023
January 27, 2023
Via
Benzinga
YMAB NOTICE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - YMAB
January 26, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. (YMAB)
January 26, 2023
From
Glancy Prongay & Murray LLP
Via
Business Wire
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. (YMAB)
January 25, 2023
From
Law Offices of Howard G. Smith
Via
Business Wire
How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
January 25, 2023
Five biotechs have already issued layoffs in 2023. Many seem to have good potential, but time will tell if the shifts create the value analysts anticipate.
Via
MarketBeat
Topics
Workforce
Exposures
Layoff
Product Safety
Y-MABS THERAPEUTICS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess Of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Y-mAbs Therapeutics, Inc. - YMAB
January 24, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Y-mAbs Therapeutics, Inc. (YMAB) Investors
January 24, 2023
From
Glancy Prongay & Murray LLP
Via
Business Wire
NOTICE: Investors in Y-mAbs Therapeutics, Inc. with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – YMAB
January 24, 2023
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioLineRx, Enovix, Southwest Airlines, and Y-mAbs and Encourages Investors to Contact the Firm
January 23, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Y-mAbs Therapeutics (YMAB) Investors
January 23, 2023
From
The Law Offices of Frank R. Cruz
Via
Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Y-mAbs Therapeutics, Inc. (YMAB) Investors
January 23, 2023
From
Law Offices of Howard G. Smith
Via
Business Wire
ROSEN, A TOP RANKED LAW FIRM, Encourages Y-mAbs Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - YMAB
January 22, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Product Safety
Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Y-mAbs Therapeutics, Inc. (YMAB)
January 20, 2023
From
Robbins LLP
Via
Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Y-mAbs Therapeutics, Inc. (YMAB) on Behalf of Investors
January 20, 2023
From
Glancy Prongay & Murray LLP
Via
Business Wire
Y-MABS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Y-mAbs Therapeutics, Inc. and Encourages Investors to Contact the Firm
January 19, 2023
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Y-mAbs Therapeutics, Inc. (YMAB) on Behalf of Investors
January 19, 2023
From
Law Offices of Howard G. Smith
Via
Business Wire
Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Y-mAbs Therapeutics, Inc. (YMAB) Investors
January 19, 2023
From
Kirby McInerney LLP
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.